Atossa Therapeutics - ATOS Revenue Change YoY (Last 12 Months)

Graphic logo of Atossa Pharma (ATOS)

Atossa Therapeutics develops targeted breast cancer therapies, leveraging patent protection amidst costly R&D expenditures. The monetization of unique formulas ensures long-term demand for its drugs. The current year-over-year revenue growth rate (TTM) is recorded at 0.00, confirming the company's financial momentum. Looking ahead, Atossa Therapeutics plans to complete clinical phases and secure a major licensing partner.

Atossa (ATOS) Sales Growth YoY (Last Twelve Months): for the period 02/11/2024 - 11/16/2026

atossatherapeutics.com (ATOS) - metric breakdowns and financial figures

- market price and analyst price targets:
Fundamental company valuation:Atossa Therapeutics
Signature product of Atossa Therapeutics

For Atossa Therapeutics (ATOS), whose success depends on Endoxifen clinical trials within the defensive oncology sector, the TTM annual revenue growth serves as an indicator of development commercialization. This metric compares revenue over the last twelve months with the same period last year, allowing investors to filter out market noise and avoid freezing capital in the event of negative fundamental sales trends.